6 pharmaceutical companies are challenging on the exclusive sale rights for Ezetimibe

Published: 2014-10-31 13:28:13

Updated: 2014-10-31 13:28:13

While domestic pharmaceutical companies in Korea are competing for the Rosuvastatin-Ezetimibe complex, competition for patent on the complex has opened up as well.

Especially, since the exclusive sale rights will be given on the developed products due to the patent linkage system that will be enforced on the next March, competing pharmaceutical companies are putting the best efforts on strateg...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.